Journey Medical Inventory 2020-2024 | DERM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Journey Medical inventory from 2020 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Journey Medical inventory from 2020 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$76.9B
Takeda Pharmaceutical (TAK)	$43.9B
Merck (MKKGY)	$20.8B
Astellas Pharma (ALPMY)	$20.2B
Sandoz Group AG (SDZNY)	$19.6B
United Therapeutics (UTHR)	$17.7B
Summit Therapeutics (SMMT)	$15.4B
Neurocrine Biosciences (NBIX)	$12.7B
Shionogi (SGIOY)	$12.3B
Catalent (CTLT)	$10.9B
Madrigal Pharmaceuticals (MDGL)	$7.4B
Jazz Pharmaceuticals (JAZZ)	$6.9B
Orion OYJ (ORINY)	$6.8B
Ionis Pharmaceuticals (IONS)	$5.7B
Corcept Therapeutics (CORT)	$5.7B
Crinetics Pharmaceuticals (CRNX)	$4.7B
PTC Therapeutics (PTCT)	$3.3B
Dyne Therapeutics (DYN)	$3B
Catalyst Pharmaceuticals (CPRX)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Soleno Therapeutics (SLNO)	$2.2B
NewAmsterdam Pharma (NAMS)	$2B
Recursion Pharmaceuticals (RXRX)	$2B
Centessa Pharmaceuticals (CNTA)	$1.8B
Harrow (HROW)	$1.7B
Ocular Therapeutix (OCUL)	$1.7B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Xencor (XNCR)	$1.6B
Ardelyx (ARDX)	$1.5B